Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization

Adipocyte

Volumn 7, Issue 2, 2018, Pages 121-128

  Xu, Liang ^a   Ota, Tsuguhito ^a,b  

^a KANAZAWA UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

adipose tissue macrophage; empagliflozin; fat browning; inflammation; insulin resistance

Indexed keywords

ADIPONECTIN; CANAGLIFLOZIN; DAPAGLIFLOZIN; FIBROBLAST GROWTH FACTOR 21; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 4; INTERLEUKIN 6; IPRAGLIFLOZIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHLORIZIN; RANTES; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; TUMOR NECROSIS FACTOR; UNCOUPLING PROTEIN 1;

BODY WEIGHT LOSS; BROWN ADIPOSE TISSUE; CYTOKINE PRODUCTION; DRUG SAFETY; DRUG TOLERABILITY; FATTY ACID OXIDATION; FLOW CYTOMETRY; GLUCOSURIA; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; KUPFFER CELL; MACROPHAGE ACTIVATION; MACROPHAGE POLARIZATION; MEDICAL PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; DRUG EFFECT; MACROPHAGE; METABOLISM; NONALCOHOLIC FATTY LIVER; PHARMACOLOGY;

ADIPOSE TISSUE, BROWN; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MACROPHAGE ACTIVATION; MACROPHAGES; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85060618900     PISSN: 21623945     EISSN: 2162397X     Source Type: Journal    
DOI: 10.1080/21623945.2017.1413516     Document Type: Note

References (61)

1. Cangoz S, Chang YY, Chempakaseril SJ, et al. et al. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. J Clin Pharm Ther. 2013;38(5):350–9 doi:10.1111/jcpt.12077
2. Van den Heuvel LP, Assink K, Willemsen M, et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet. 2002;111(6):544–7 doi:10.1007/s00439-002-0820-5
3. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133–41 doi:10.2215/CJN.04010609
4. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304(2):F156–67 doi:10.1152/ajprenal.00409.2012
5. Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–8 doi:10.1111/dom.12081
6. Rosenwasser RF, Rosenwasser JN, Sutton D, et al. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2014;50(11):739–45 doi:10.1358/dot.2014.50112232267
7. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014;57(5):891–901 doi:10.1007/s00125-014-3196-x
8. Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014;3:212264. doi:10.7573/dic.212264
9. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–80 doi:10.2147/DDDT.S50773
10. White JR, Jr. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: A review of the evidence. Ann Pharmacother. 2015; doi:10.1177/1060028015573564
11. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology. 2013;1(3):208–219 doi:10.1016/s2213-8587(13)70084-6
12. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90 doi:10.1111/j.1463-1326.2011.01517.x
13. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metabolism and Pharmacokinetics. 2013;28(3):213–219 doi:10.2133/dmpk.DMPK-12-RG-082
14. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–25 doi:10.1007/s40262-013-0126-x
15. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clinical Pharmacology in Drug Development. 2013;2(2):152–161 doi:10.1002/cpdd.16
16. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7 doi:10.1038/nature05485
17. Kitade H, Sawamoto K, Nagashimada M, et al. et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes. 2012;61(7):1680–90 doi:10.2337/db11-1506/-/DC1
18. Huh JY, Park YJ, Ham M, et al. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells. 2014;37(5):365–71 doi:10.14348/molcells.2014.0074
19. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84 doi:10.1172/JCI29881
20. Dey A, Allen J, Hankey-Giblin PA. Ontogeny and polarization of macrophages in inflammation: blood monocytes versus tissue macrophages. Front Immunol. 2014;5:683. doi:10.3389/fimmu.2014.00683
21. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35 doi:10.1038/nri978
22. Brown BN, Ratner BD, Goodman SB, et al. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials. 2012;33(15).3792–802 doi:10.1016/j.biomaterials.2012.02034
23. Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, et al. Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? Front Immunol. 2014;5:470. doi:10.3389/fimmu.2014.00470
24. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha_ direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91 doi:10.1126/science.7678183
25. Xu H, Barnes GT, Yang Q, et al. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30 doi:10.1172/JCI19451
26. Feuerer M, Herrero L, Cipolletta D, et al. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15(8):930–9 doi:10.1038/nm.2002
27. Molofsky AB, Nussbaum JC, Liang HE, et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med. 2013;210(3):535–49 doi:10.1084/jem.20121964
28. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45 doi:10.1146/annurev-immunol-031210-101322
29. Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology. 2014;59(5):2034–42 doi:10.1002/hep.26754
30. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46 doi:10.1146/annurev-physiol-021909-135846
31. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. Science. 2013;342(6161):1242974. doi:10.1126/science.1242974
32. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95 doi:10.1172/JCI59643
33. Jager J, Aparicio-Vergara M, Aouadi M. Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells. J Intern Med. 2016;280(2):209–20 doi:10.1111/joim.12483
34. Xu L, Kitade H, Ni Y, et al. Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules. 2015;5(3):1563–79 doi:10.3390/biom5031563
35. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389(6651):610–4 doi:10.1038/39335
36. Tahara A, Kurosaki E, Yokono M, et al. et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1-3):246–55 doi:10.1016/j.ejphar.2013.05.014
37. Terami N, Ogawa D, Tachibana H, et al. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777. doi:10.1371/journal.pone.0100777
38. Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149 doi:10.1016/j.ebiom.2017.05.028
39. Haslam DW, James WPT. Obesity. The Lancet. 2005;366(9492):1197–1209 doi:10.1016/s0140-6736(05)67483-1
40. Obata A, Kubota N, Kubota T, et al. et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2016;157(3):1029–42 doi:10.1210/en.2015-1588
41. Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20(8):1645–52 doi:10.1038/oby.2012.59
42. Nakano S, Katsuno K, Isaji M, et al. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol. 2015;5(3):190–8 doi:10.1016/j.jceh.2015.02.005
43. Qiang S, Nakatsu Y, Seno Y, et al. et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015;7:104. doi:10.1186/s13098-015-0102-8
44. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65(7):2032–8 doi:10.2337/db16-0049
45. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose votransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190–1195 doi:10.2337/db15-1356
46. + /glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–94 doi:10.2337/db16-0058
47. Adya R, Tan BK, Randeva HS. Differential effects of leptin and adiponectin in endothelial angiogenesis. J Diabetes Res. 2015;2015:648239. doi:10.1155/2015/648239
48. Lowell BB, Spiegelman BM. Towards a molecular understanding of adaptive thermogenesis. Nature. 2000;404(6778):652–60 doi:10.1038/35007527
49. Cohen P, Levy JD, Zhang Y, et al. et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell. 2014;156(1-2):304–16 doi:10.1016/j.cell.2013.12.021
50. Seale P, Bjork B, Yang W, et al. et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008;454(7207):961–7 doi:10.1038/nature07182
51. Wu J, Cohen P, Spiegelman BM. Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev. 2013;27(3):234–50 doi:10.1101/gad.211649.112
52. Lo KA, Sun L. Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes. Biosci Rep. 2013;33(5): doi:10.1042/BSR20130046
53. Nguyen KD, Qiu Y, Cui X, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;480(7375):104–8 doi:10.1038/nature10653
54. Qiu Y, Nguyen KD, Odegaard JI, et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell. 2014;157(6):1292–308 doi:10.1016/j.cell.2014.03.066
55. Hui X, Gu P, Zhang J, et al. et al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell Metab. 2015;22(2):279–90 doi:10.1016/j.cmet.2015.06.004
56. Zhao Y, Gao P, Sun F, et al. et al. Sodium intake regulates glucose homeostasis through the PPARdelta/adiponectin-mediated SGLT2 pathway. Cell Metab. 2016;23(4):699–711 doi:10.1016/j.cmet.2016.02.019
57. Tanizawa Y, Araki E, Tobe K, et al. Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycaemic agents in Japanese patients with type 2 diabetes. Diabetologia. 2013;56:S82–S83
58. Inagaki T, Dutchak P, Zhao G, et al. et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415–25 doi:10.1016/j.cmet.2007.05.003
59. Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426–37 doi:10.1016/j.cmet.2007.05.002
60. Kharitonenkov A, Shiyanova TL, Koester A, et al. et al. FGF21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627–35 doi:10.1172/JCI23606
61. Fisher FM, Kleiner S, Douris N, et al. et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26(3):271–81 doi:10.1101/gad.177857.111